The purpose of this study is to evaluate efficacy and safety of the combined use of oral Vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) >= to 40%
Contact phone
517-364-5760
Contact email
[email protected]
Principal investigator
Chad Link, DO
Trial Category
Heart & Vascular
Trial SubCategory
Atrial Fibrillation
Webform